Study Comparing the Efficacy of Peripherally Inserted Central Catheter (PICC) Placement With the Addition of Cyanoacrylate Glue Versus PICC Placement Alone in Patients With Cancer.
NCT ID: NCT05944900
Last Updated: 2024-09-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
98 participants
INTERVENTIONAL
2023-08-02
2024-07-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Tissue Glue on PICC and Midline Catheters Insertion Sites
NCT04900740
Iterative PICC Placement Versus Long Term Device
NCT02784730
Tunneled Peripherally Inserted Central Catheter (PICC) in Adult Patients and Associated Outcomes
NCT06365528
Effectiveness of Cyanoacrylate Glue in the Fixation of Midline and Peripherally Inserted Central Catheters in Hospitalized Adult Patients: Randomised Clinical Trial (CIANO-ETI)
NCT05299060
Vascular Access in Cancer Patients - PICC vs PORT in a Randomized Controlled Trial.
NCT01971021
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Their placement requires aseptic surgical conditions, and a team trained in the procedure, sometimes grouped together in a Vascular Access Unit (UAV).
A PICC is inserted by puncturing the skin and subcutaneous tissues, and securing the catheter with a "Statlock" type stabilizer. The catheter exit point must be covered, at a minimum by a sterile occlusive dressing with a transparent semi-permeable membrane, otherwise referred to as a "transparent dressing".
According to available data, tissue puncture results in bleeding at the puncture site in 25% to 40% of procedures. This bleeding necessitates the application of a sterile compress prior to covering with a transparent dressing. The skin puncture site (also known as the catheter exit point) requires the dressing to be repeated on D1 after insertion.
To sum up:
* If there is no bleeding, there is no need to apply a compress, and the dressing can be changed on D8 after application;
* In the presence of bleeding, a compress is applied and dressing change is mandatory on D1 after application.
PICC placement combined with the use of cyanoacrylate glue would reduce the risk of bleeding, and therefore the need to use of a compress, compared with a standard procedure (without the use of glue).
On this basis, the investigators propose to conduct a randomized, prospective, single-center trial comparing the efficacy of peripherally inserted central catheter (PICC) with the addition of cyanoacrylate glue versus PICC placement alone (without glue) in patients with cancer.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
PICC placement according to standard practice + cyanoacrylate glue
PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).
The catheter will be secured by the Statlock system. Cyanoacrylate glue will be applied on the catheter exit point in accordance with the instructions for use.
A transparent dressing will be applied, with a compress in the event of bleeding.
Cyanoacrylate glue application
The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.
Cyanoacrylate glue should be applied in accordance with the instructions for use.
Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly.
PICC placement according to standard practice
PICC placement will be performed according to standard practice (Safe Insertion of PICC protocol (SIP2) steps).
The catheter will be secured by the Statlock system. A transparent dressing will be applied, with a compress in the event of bleeding.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cyanoacrylate glue application
The wound must be positioned in a horizontal plane, and the glueapplied uniformly overhanging the wound. Cyanoacrylate glue is contraindicated when adhesion cannot be achieved.
Cyanoacrylate glue should be applied in accordance with the instructions for use.
Wound-closing properties are only fully achieved once the first layer has fully polymerized. This depends on skin type, skin hydration and ambient humidity. If a second layer is applied, the polymerization time is extended accordingly.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with a histological diagnosis of cancer
* Indication for central line chemotherapy or immunotherapy
* Placement of a single-lumen PICC in the non-tunneled upper limb planned on an ambulatory basis at the Centre
* Planned duration of PICC use \> 30 days
* Dated and signed informed consent, indicating that the patient has been informed of all relevant aspects of the study prior to inclusion;
* Patient covered by a health insurance plan
Exclusion Criteria
* Patient with known allergy to cyanoacrylates, Violet D\&C or formaldehyde;
* Patient not reachable by telephone ;
* Patient under guardianship;
* Patient does not speak French.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Leon Berard
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Grégoire WALLON, MD
Role: PRINCIPAL_INVESTIGATOR
Centre Leon Berard
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Léon Bérard
Lyon, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ET23-122
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.